Compare DRCT & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRCT | MBAI |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.6M |
| IPO Year | 2022 | N/A |
| Metric | DRCT | MBAI |
|---|---|---|
| Price | $4.10 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $330.00 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 23.7K |
| Earning Date | 11-06-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,369,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.59 |
| 52 Week High | $80.85 | $3.13 |
| Indicator | DRCT | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 90.17 | N/A |
| Support Level | $1.58 | N/A |
| Resistance Level | $2.98 | N/A |
| Average True Range (ATR) | 0.44 | 0.00 |
| MACD | 0.29 | 0.00 |
| Stochastic Oscillator | 70.16 | 0.00 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.